Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era

NCT04624971 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04624971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04624971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
Lead sponsor
Sun Yat-sen University
Phase
Observational
Overall status
Unknown status
Start date
November 30, 2020
Completion date
November 30, 2020
Enrollment
2,000 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma